CLAIMS

Claim 1. A composition for use in inhibiting myofibrosis, comprising:

quercetin or a glycoside thereof as an active ingredient.

Claim 2. The composition according to claim 1,

wherein the composition inhibits the differentiation process from muscle satellite cells into myofibroblasts.

Claim 3. The composition according to claim 1 or 2,

wherein the composition has an effect of improving muscle quality.

Claim 4. The composition according to any one of claims 1 to 3,

wherein the composition has an effect of improving motor function.

Claim 5. The composition according to any one of claims 1 to 4,

wherein the composition has an effect of increasing muscle mass.

Claim 6. The composition according to any one of claims 1 to 5,

wherein the composition has an effect of inhibiting muscle atrophy.

Claim 7. The composition according to any one of claims 1 to 6,

wherein the composition has an effect of inhibiting

accumulation of extracellular matrix in muscle.

Claim 8. The composition according to claim 7,

wherein the extracellular matrix is at least one of collagen or an advanced glycation end product.

Claim 9. The composition according to any one of claims 1 to 8,

which is a food, beverage, or oral pharmaceutical product.

Claim 10. The composition according to any one of claims 1 to 9,

wherein the composition is labeled as having one or more of the following effects: inhibition, prevention, or amelioration of myofibrosis; improvement of muscle quality; improvement of motor function; increase in muscle mass; and inhibition of muscle atrophy, or is labeled for use in achieving one of more the above effects.

Claim 11. Use of quercetin or a glycoside thereof in the manufacture of a medicament for inhibiting myofibrosis.

Claim 12. Use of quercetin or a glycoside thereof in the manufacture of a medicament for inhibiting the differentiation process from muscle satellite cells into myofibroblasts.

Claim 13. The use of claim 11 or 12,

wherein the medicament has an effect of improving muscle quality.

Claim 14. The use according to any one of claims 11 to

13,

wherein the medicament has an effect of improving motor function.

Claim 15. The use according to any one of claims 11 to 14,

wherein the medicament has an effect of increasing muscle mass.

Claim 16. The use according to any one of claims 11 to 15,

wherein the medicament has an effect of inhibiting muscle atrophy.

Claim 17. The use according to any one of claims 11 to 16,

wherein the medicament has an effect of inhibiting accumulation of extracellular matrix in muscle.

Claim 18. The use according to claim 17,

wherein the extracellular matrix is at least one of collagen or an advanced glycation end product.

Claim 19. The use according to any one of claims 11 to 18,

wherein the medicament is a food, beverage, or oral pharmaceutical product.

Claim 20. The use according to any one of claims 11 to 19,

wherein the medicament is labeled as having one or more of the following effects: inhibition, prevention, or amelioration of myofibrosis; improvement of muscle quality;

improvement of motor function; increase in muscle mass; and inhibition of muscle atrophy, or is labeled for use in achieving one of more the above effects.